Yongqian Shu

Yongqian Shu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Gene
Verified
Journal Article
Closed access
HZHaifeng Zhu
Haifeng Zhu
XLXiaoqin Li
Xiaoqin Li
XZXiaomei Zhang
Xiaomei Zhang
DCDeyu Chen
Deyu Chen
DLDan Li
Dan Li
DWDeqiang Wang
Deqiang Wang

1 October 2019 in Gene
Verified
Journal Article
Closed access
DWDeqiang Wang
Deqiang Wang
XLXiaoqin Li
Xiaoqin Li
BSBo Shen
Bo Shen
XCXiaofeng Chen
Xiaofeng Chen
YSYongqian Shu
Yongqian Shu

1 November 2020 in Annals of Oncology
Verified
Journal Article
Closed access
XCX. Chen
X. Chen
WLW. Li
W. Li
XWX. Wu
X. Wu
FZF. Zhao
F. Zhao
HWH. Wu
H. Wu
YSYongqian Shu
Yongqian Shu

5 July 2024 in Medicine
Verified
Journal Article
Open access
YLYiqian Liu
Yiqian Liu
LMLiyun Miao
Liyun Miao
XCXiao Chen
Xiao Chen
XZXiaoli Zhu
Xiaoli Zhu
YLYan Li
Yan Li
YSYongqian Shu
Yongqian Shu
Background: Maintenance therapy could significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is effective, tolerable, and convenient in administration as a third-line treatment for NSCLC. This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC. Methods: This pooled analysis of 2 multicenter, open-label, single-arm, phase 2 clinical trials (ALTER-L014 and ALTER-L011) enrolled patients with locally advanced or metastatic NSCLC and without known sensitive mutations in China between September 2018 and January 2021. The primary outcome was progression-free survival. The secondary outcomes were objective response rate, disease control rate, overall survival, and safety. Results: The data of 23 patients were pooled, with 15 from ALTER-L014 and 8 from ALTER-L011. At the cutoff date of June 13, 2021, the median progression-free survival since the start of maintenance therapy was 5.95 (95% confidence interval, 4.30–8.80) months. Nineteen patients had stable disease, 1 had a partial response and 3 had progressive disease. The objective response rate was 4.35%, while disease control rate was 86.96%. The median overall survival of the patients since the start of maintenance therapy was 18.60 (95% confidence interval, 6.87–22.80) months. The incidence of adverse events of grade ≥ 3 was 21.7%. Conclusion: Anlotinib might offer a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC without known sensitive mutations after standard first-line platinum-based chemotherapy.